89 related articles for article (PubMed ID: 2788028)
1. Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
Froom P; Aghai E; Kinarty A; Lahat N
Cancer; 1989 Sep; 64(5):1038-40. PubMed ID: 2788028
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
3. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
4. [The role of natural killer cell activity in the pathogenesis of chronic myeloproliferative diseases].
Guseva SA
Lik Sprava; 1993 Jul; (8):70-3. PubMed ID: 8079482
[TBL] [Abstract][Full Text] [Related]
5. Immunologic dysfunction in the myeloproliferative disorders.
DiBella NJ; Brown GL
Cancer; 1978 Jul; 42(1):149-58. PubMed ID: 276412
[TBL] [Abstract][Full Text] [Related]
6. Reduced natural killer activity in patients with Fanconi's anemia and in family members.
Froom P; Aghai E; Dobinsky JB; Quitt M; Lahat N
Leuk Res; 1987; 11(2):197-9. PubMed ID: 3493394
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin.
Mori S; Jewett A; Cavalcanti M; Murakami-Mori K; Nakamura S; Bonavida B
Int J Oncol; 1998 May; 12(5):1165-70. PubMed ID: 9538144
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH
Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377
[TBL] [Abstract][Full Text] [Related]
9. Blood and neoplastic diseases. Myeloproliferative disorders.
Lewis SM; Szur L
Br Med J; 1974 Nov; 4(5941):399-402. PubMed ID: 4425895
[No Abstract] [Full Text] [Related]
10. [The treatment of myeloproliferative syndromes].
Maurice P
Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.
Struyf NJ; Snoeck HW; Bridts CH; De Clerck LS; Stevens WJ
Ann Rheum Dis; 1990 Sep; 49(9):690-3. PubMed ID: 1700674
[TBL] [Abstract][Full Text] [Related]
12. Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
Riley CH; Jensen MK; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM
Blood; 2011 Aug; 118(8):2170-3. PubMed ID: 21708889
[TBL] [Abstract][Full Text] [Related]
13. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
Brooks CG; Holscher M; Urdal D
J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
[TBL] [Abstract][Full Text] [Related]
14. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
15. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.
Handa K; Suzuki R; Matsui H; Shimizu Y; Kumagai K
J Immunol; 1983 Feb; 130(2):988-92. PubMed ID: 6294182
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell function and modulation by alpha IFN and IL2 in AIDS patients and prodromal subjects.
Lew F; Tsang P; Solomon S; Selikoff IJ; Bekesi JG
J Clin Lab Immunol; 1984 Jul; 14(3):115-21. PubMed ID: 6237206
[TBL] [Abstract][Full Text] [Related]
17. Modulation of in vitro porcine natural killer cell activity by recombinant interleukin-1 alpha, interleukin-2 and interleukin-4.
Knoblock KF; Canning PC
Immunology; 1992 Jun; 76(2):299-304. PubMed ID: 1634252
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
19. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
[TBL] [Abstract][Full Text] [Related]
20. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
